AIM ImmunoTech (AIM) News Today $0.25 -0.16 (-38.42%) Closing price 05/20/2026 04:10 PM EasternExtended Trading$0.25 0.00 (-0.04%) As of 06:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock AIM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period AIM ImmunoTech Inc. Announces Registered Direct Offering of Common Stock and Concurrent Private Placement of WarrantsMay 20 at 3:11 PM | quiverquant.comQAIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private PlacementMay 20 at 3:02 PM | globenewswire.comCMMI Institute Completes Pilot for New AI Maturity (AIM) FrameworkMay 19 at 12:03 PM | businesswire.comAIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting ...May 19 at 8:52 AM | finance.yahoo.comAIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical PrioritiesMay 19 at 8:02 AM | globenewswire.comAIM ImmunoTech (NYSEAMERICAN:AIM) Trading Up 61.3% - Here's What HappenedMay 19 at 2:16 AM | americanbankingnews.comTranscript: Aimia Q1 2026 Earnings Conference CallMay 14, 2026 | finance.yahoo.comAIM ImmunoTech Reports Positive Data from Named Patient Program and Interim Results from Phase 2 Study of Ampligen® for Late-Stage Pancreatic CancerMay 14, 2026 | quiverquant.comQAIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic CancerMay 14, 2026 | globenewswire.comWhy did AIM stock plummet 35% today?May 8, 2026 | msn.comAIM ImmunoTech Announces Agreement to Exercise Existing Warrants for $4.2 Million in Gross ProceedsMay 8, 2026 | quiverquant.comQAIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross ProceedsMay 8, 2026 | globenewswire.comAIM ImmunoTech Inc. Announces Positive Phase 2 Clinical Trial Results of Ampligen® in Recurrent Ovarian Cancer Collaboration with MerckMay 7, 2026 | quiverquant.comQAIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination PotentialMay 7, 2026 | globenewswire.comAIM ImmunoTech (AIM) price target decreased by 54.50% to 10.20April 29, 2026 | msn.comAIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and ...April 16, 2026 | markets.businessinsider.comAIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer TreatmentApril 13, 2026 | quiverquant.comQAIM ImmunoTech Provides Routine Update on Annual FilingsApril 13, 2026 | globenewswire.comAIM ImmunoTech Expands At-The-Market Equity Offering CapacityApril 10, 2026 | tipranks.comWhat's going on with AIM ImmunoTech stock Friday?March 20, 2026 | msn.comWhy did AIM stock more than double in pre-market today?March 18, 2026 | msn.comAIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint InhibitorsMarch 18, 2026 | globenewswire.comAIM ImmunoTech Inc. Announces Successful Closure of $1.8 Million Rights Offering for Ampligen® DevelopmentMarch 6, 2026 | quiverquant.comQAIM ImmunoTech Announces Closing of its Rights OfferingMarch 6, 2026 | globenewswire.comAIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 MillionMarch 4, 2026 | markets.businessinsider.comAIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic CancerMarch 2, 2026 | globenewswire.comAIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights OfferingFebruary 27, 2026 | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026February 26, 2026 | finanznachrichten.deAIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026February 25, 2026 | finance.yahoo.comAIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic CancerFebruary 23, 2026 | markets.businessinsider.comAIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic CancerFebruary 23, 2026 | globenewswire.comCORRECTION: AIM ImmunoTech Announces Commencement of Rights OfferingFebruary 12, 2026 | globenewswire.comAIM ImmunoTech to Participate in Live Virtual Investor Closing Bell EventFebruary 12, 2026 | markets.businessinsider.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces Commencement of Rights OfferingFebruary 11, 2026 | finanznachrichten.deAIM ImmunoTech Announces Commencement of Rights OfferingFebruary 11, 2026 | globenewswire.comAIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialFebruary 6, 2026 | globenewswire.comAIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi ...February 5, 2026 | markets.businessinsider.comAIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerFebruary 5, 2026 | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights OfferingFebruary 3, 2026 | finanznachrichten.deAIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights OfferingJanuary 27, 2026 | markets.businessinsider.comAIM ImmunoTech Inc. Announces Amended Dates for Rights Offering, Expected to Raise $12 MillionJanuary 27, 2026 | quiverquant.comQAIM ImmunoTech Inc. Announces Key Details of Proposed $12 Million Rights Offering for Security HoldersJanuary 23, 2026 | quiverquant.comQAIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights OfferingJanuary 23, 2026 | globenewswire.comAIM ImmunoTech Highlights Ampligen Development Risks and PlansJanuary 15, 2026 | theglobeandmail.comAIM ImmunoTech Announces Stock DividendDecember 31, 2025 | finance.yahoo.comAIM ImmunoTech Inc. Announces Stock Dividend of One Share for Every 1,000 Shares HeldDecember 30, 2025 | quiverquant.comQSintana Energy begins trading on London's AIM marketDecember 23, 2025 | proactiveinvestors.comSintana Energy to begin trading on London's AIMDecember 18, 2025 | proactiveinvestors.comAscendiant Capital maintains AIM ImmunoTech (AIM) buy recommendationDecember 8, 2025 | msn.comAIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell SeriesDecember 1, 2025 | markets.businessinsider.com Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIM Media Mentions By Week AIM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼0.800.38▲Average Medical News Sentiment AIM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼112▲AIM Articles Average Week Get the Latest News and Ratings for AIM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AIM ImmunoTech and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ADXN News NCNA News CELZ News LIMN News BFRG News NKGN News ATON News TNFA News BCLI News GRTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:AIM) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
